Autocrine ATP release coupled to extracellular pyrophosphate accumulation in vascular smooth muscle cells.
Extracellular inorganic pyrophosphate (PP(i)) is a potent suppressor of physiological calcification in bone and pathological calcification in blood vessels. Ectonucleotide pyrophosphatase/phosphodiesterases (eNPPs) generate PP(i) via the hydrolysis of ATP released into extracellular compartments by poorly understood mechanisms. Here we report that cultured vascular smooth muscle cells (VSMC) from rat aorta generate extracellular PP(i) via an autocrine mechanism that involves ATP release tightly coupled to eNPP activity. The nucleotide analog beta,gamma-methylene ATP (MeATP or AMPPCP) was used to selectively suppress ATP metabolism by eNPPs but not the CD39-type ecto-ATPases. In the absence of MeATP, VSMC generated extracellular PP(i) to accumulate >or=600 nM within 2 h while steadily maintaining extracellular ATP at 1 nM. Conversely, the presence of MeATP completely suppressed PP(i) accumulation while increasing ATP accumulation. Probenecid, which inhibits PP(i) efflux dependent on ANK, a putative PP(i) transporter or transport regulator, reduced extracellular PP(i) accumulation by approximately twofold. This indicates that autocrine ATP release coupled to eNPP activity comprises >or=50% of the extracellular PP(i)-generating capacity of VSMC. The accumulation of extracellular PP(i) and ATP was markedly attenuated by reduced temperature but was insensitive to brefeldin A, which suppresses constitutive exocytosis of Golgi-derived secretory vesicles. The magnitude of extracellular PP(i) accumulation in VSMC cultures increased with time postplating, suggesting that ATP release coupled to PP(i) generation is upregulated as cultured VSMC undergo contact-inhibition of proliferation or deposit extracellular matrix.
Prosdocimo
Domenick A
DA
Dept. of Physiology, Case Western Reserve Univ. School of Medicine, 2109 Adelbert Rd., Cleveland, OH 44106, USA.
Douglas
Dezmond C
DC
Romani
Andrea M
AM
O'Neill
W Charles
WC
Dubyak
George R
GR
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D019898:Autocrine Communication; D020126:Brefeldin A / Q000494:pharmacology; D002478:Cells, Cultured; D003080:Cold Temperature; D011756:Diphosphates / Q000378:metabolism*; D004164:Diphosphonates / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D006868:Hydrolysis; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D028061:Phosphate Transport Proteins; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011339:Probenecid / Q000494:pharmacology; D011755:Pyrophosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D015854:Up-Regulation
C498769:Ankh protein, mouse; D011756:Diphosphates; D004164:Diphosphonates; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D028061:Phosphate Transport Proteins; D020126:Brefeldin A; C005147:5'-adenylyl (beta,gamma-methylene)diphosphonate; C027474:methylene diphosphonate; D000255:Adenosine Triphosphate; D010727:Phosphoric Diester Hydrolases; C065962:ectonucleotide pyrophosphatase phosphodiesterase 1; D011755:Pyrophosphatases; D011339:Probenecid